Aug 30, 2021 8:06am EDT NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
Aug 26, 2021 6:48am EDT NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies
Aug 23, 2021 9:33am EDT Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary
Aug 18, 2021 11:53am EDT NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19
Aug 09, 2021 1:13pm EDT NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia
